Linda K. Morse | Researchain

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where Linda K. Morse is active.

Explore More

Publication

Featured researches published by Linda K. Morse.

Cancer | 2008

Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma

David M. Jackman; Hedy L. Kindler; Beow Y. Yeap; Panos Fidias; Ravi Salgia; Joan Lucca; Linda K. Morse; Patricia Ostler; Bruce E. Johnson; Pasi A. Jänne

We conducted a phase 2, multicenter, open‐label study of erlotinib plus bevacizumab in patients with malignant pleural mesothelioma who had previously received 1 prior chemotherapy regimen. These agents have activity in non–small cell lung cancer, but their role in mesothelioma is unclear. The primary endpoint is response rate. Secondary endpoints include time to progression, survival, and toxicity.

Oncotarget | 2015

A Phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer

David M. Jackman; Leigh Anne Cioffredi; L. J. A. M. Jacobs; Farhana Sharmeen; Linda K. Morse; Joan Lucca; Scott R. Plotkin; Paul J. Marcoux; Michael S. Rabin; Tom J. Lynch; Bruce E. Johnson; Santosh Kesari

Seminars in Oncology Nursing | 2006

EGFR-Targeted Therapy and Related Skin Toxicity

Linda K. Morse; Pamela Calarese

Journal of Clinical Oncology | 2009

Phase II trial of erlotinib in chemotherapy-naive women with advanced pulmonary adenocarcinoma

David M. Jackman; Leigh-Anne Cioffredi; Neal I. Lindeman; Linda K. Morse; Joan Lucca; D. Weckstein; Mark S. Huberman; Thomas J. Lynch; Bruce E. Johnson; Pasi A. Jänne

Journal of Clinical Oncology | 2007

Phase II study of erlotinib in chemo-naive women with advanced pulmonary adenocarcinoma

David M. Jackman; Neal I. Lindeman; Joan Lucca; Linda K. Morse; Michael S. Rabin; J. P. Marcoux; Mark S. Huberman; Bruce E. Johnson; Pasi A. Jänne

ASCO Meeting Abstracts | 2006

Phase II trial of erlotinib in elderly patients (age > 70) with previously untreated advanced non-small cell lung cancer (NSCLC): An analysis of quality of life and symptom response

David M. Jackman; Beow Y. Yeap; Joan Lucca; Patricia Ostler; Linda K. Morse; P. Fidias; Thomas J. Lynch; Jennifer S. Temel; Bruce E. Johnson; Pasi A. Jänne

Journal of Clinical Oncology | 2017

A phase II trial of erlotinib for EGFR mutant NSCLC to prospectively assess biopsy feasibility and acquired resistance at disease progression.

Amanda J. Redig; Myriam Taibi; Geoffrey R. Oxnard; David Boucher; Michael S. Rabin; J. Paul Marcoux; Leena Gandhi; Mark S. Huberman; Deepa Rangachari; Joan Lucca; Linda K. Morse; MaChristine Andan; Bruce E. Johnson; Daniel B. Costa; Pasi A. Jänne; David M. Jackman

Journal of Thoracic Oncology | 2007

P3-096: Phase II study of erlotinib in chemo–naïve women with advanced pulmonary adenocarcinoma.

David M. Jackman; Neal I. Lindeman; Joan Lucca; Linda K. Morse; Michael S. Rabin; J.P. Marcoux; Mark S. Huberman; Bruce E. Johnson; Pasi A. Jänne

Archive | 2011

SELF-REPORTED ADHERENCE TO ERLOTINIB BY ELDERS WITH LUNG CANCER

Linda K. Morse; Joan Lucca; Pat Ostler

Journal of Thoracic Oncology | 2007

Phase II study of erlotinib plus bevacizumab in patients with previously treated malignant pleural mesothelioma: P1-132

David M. Jackman; Hedy L. Kindler; P. Fidias; Ravi Salgia; Joan Lucca; Patricia Ostler; Linda K. Morse; Thomas J. Lynch; Bruce E. Johnson; Pasi A. Jänne

Explore More